Dean Bajorin
Emeritus · New York Presbyterian Hospital
Credentials: · ·
History
1981–1983- 1978–1981
- 1974–1978
- 1970–1974
Research
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
Nature Genetics · 2019 · 3,156 citations
The Lancet · 2016 · 2,972 citations
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
New England Journal of Medicine · 2017 · 2,802 citations
- GE
98 papers
- RM
92 papers
- JR
67 papers
- GI
65 papers
- BB
61 papers
- HA
59 papers
- HH
55 papers
- JS
51 papers
Grants
- 2018–2025
National Cancer Institute · P50
Contact PI · $9.5M · Sloan-Kettering Inst Can Research
- 1977–2024
Investigational Cancer Therapeutics Training Program (ICTTP)
National Cancer Institute · T32
Contact PI · $6.9M · Sloan-Kettering Inst Can Research
- 2017–2022
I. Institutional Career Development Core
National Center for Advancing Translational Sciences · KL2
PI · $4.9M · Weill Medical Coll of Cornell Univ
- 1999–2010
MSKCC Clinical Research Methodology Curriculum
National Center for Research Resources · K30
Contact PI · $649.1K · Sloan-Kettering Inst Can Research
Clinical trials
- 2013
Principal investigator · Terminated · Phase 2
Memorial Sloan Kettering Cancer Center
- 2012–2016
Principal investigator · Terminated · Phase 2
Memorial Sloan Kettering Cancer Center
- 2012–2018
Principal investigator · Completed · Phase 2
Memorial Sloan Kettering Cancer Center
- 2012–2020
Buparlisib in Metastatic Transitional Cell Carcinoma of the Urothelium
Principal investigator · Completed · Phase 2
Memorial Sloan Kettering Cancer Center